Edition:
United Kingdom

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

25.39USD
23 Apr 2018
Change (% chg)

$1.53 (+6.41%)
Prev Close
$23.86
Open
$24.04
Day's High
$25.40
Day's Low
$24.00
Volume
125,483
Avg. Vol
68,228
52-wk High
$40.56
52-wk Low
$19.32

Chart for

About

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical... (more)

Overall

Beta: --
Market Cap(Mil.): $624.06
Shares Outstanding(Mil.): 26.16
Dividend: --
Yield (%): --

Financials

  RETA.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.91 -- --
ROI: -81.36 -0.74 13.19
ROE: -- -2.80 15.00

BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome

* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME

11 Apr 2018

BRIEF-Reata Announces That Kyowa Hakko Kirin Received Sakigake Priority Review Designation For Bardoxolone Methyl In Japan

* REATA ANNOUNCES THAT KYOWA HAKKO KIRIN RECEIVED SAKIGAKE PRIORITY REVIEW DESIGNATION FOR BARDOXOLONE METHYL IN JAPAN Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial

* REATA ANNOUNCES POSITIVE TOP-LINE DATA FOR TREATMENT OF PH-ILD WITH BARDOXOLONE METHYL FROM THE PHASE 2 LARIAT TRIAL

22 Mar 2018

BRIEF-Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64

* REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

02 Mar 2018

BRIEF-Reata Announces Top-Line Data From Study Of Patients With Mitochondrial Myopathies

* REATA ANNOUNCES TOP-LINE DATA FROM THE DOSE-ESCALATION COHORTS OF THE PHASE 2 MOTOR STUDY OF OMAVELOXOLONE IN PATIENTS WITH MITOCHONDRIAL MYOPATHIES Source text for Eikon: Further company coverage:

01 Mar 2018

BRIEF-Reata Provides Program Update On Phase 2 Rare Renal Clinical Trials

* REATA PROVIDES PROGRAM UPDATE ON PHASE 2 RARE RENAL CLINICAL TRIALS

27 Feb 2018

BRIEF-Reata Announces Improvements In Kidney Function With Bardoxolone Methyl Maintained For Two Years In Pah Patients From Lariat Trial

* REATA ANNOUNCES IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE METHYL MAINTAINED FOR TWO YEARS IN PAH PATIENTS FROM LARIAT TRIAL Source text for Eikon: Further company coverage:

12 Feb 2018

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)

07 Dec 2017

BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​

* Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing Source text : (http://bit.ly/2AG2XNP) Further company coverage:

13 Nov 2017

BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50

* Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results

13 Nov 2017

Earnings vs. Estimates